Catalyst Pharmaceuticals Stock Performance
| CPRX Stock | USD 21.03 0.42 1.96% |
The firm shows a Beta (market volatility) of 1.09, which signifies a somewhat significant risk relative to the market. Catalyst Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Catalyst Pharmaceuticals is expected to follow. At this point, Catalyst Pharmaceuticals has a negative expected return of -0.0559%. Please make sure to confirm Catalyst Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Catalyst Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Catalyst Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Catalyst Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (1.96) | Five Day Return (4.23) | Year To Date Return (2.28) | Ten Year Return 272.21 | All Time Return 244.75 |
1 | Disposition of 44000 shares by Ingenito Gary of Catalyst Pharmaceuticals at 23.63 subject to Rule 16b-3 | 05/14/2025 |
2 | Disposition of 200000 shares by Ingenito Gary of Catalyst Pharmaceuticals at 23.68 subject to Rule 16b-3 | 05/15/2025 |
3 | Disposition of 14000 shares by Miller Steve of Catalyst Pharmaceuticals subject to Rule 16b-3 | 05/19/2025 |
4 | Why Catalyst Pharmaceutical is a Top Growth Stock for the Long-Term | 06/03/2025 |
5 | Disposition of 171748 shares by Patrick McEnany of Catalyst Pharmaceuticals at 26.11 subject to Rule 16b-3 | 06/09/2025 |
6 | Disposition of 1600 shares by Preethi Sundaram of Catalyst Pharmaceuticals at 26.42 subject to Rule 16b-3 | 06/11/2025 |
7 | Preethi Sundaram Implements A Sell Strategy Offloads 103K In Catalyst Pharmaceuticals Stock | 06/13/2025 |
8 | Heres Why Catalyst Pharmaceutical is a Strong Value Stock | 06/18/2025 |
9 | CPRX vs. NBIX Which Stock Is the Better Value Option | 06/23/2025 |
10 | Post-Traumatic Stress Disorder Market Set to Expand Significantly During the Study Period with Pipeline Innovation and Unmet Needs DelveInsight | 06/26/2025 |
11 | Are Investors Undervaluing Catalyst Pharmaceuticals Right Now | 06/30/2025 |
12 | Stratos Wealth Advisors LLC Makes New 2.02 Million Investment in Catalyst Pharmaceuticals, Inc. | 07/09/2025 |
13 | Hohimer Wealth Management LLC Grows Position in Catalyst Pharmaceuticals, Inc. | 07/15/2025 |
14 | What drives Catalyst Pharmaceuticals Inc. stock price - Rapid capital growth - Jammu Links News | 07/18/2025 |
| Begin Period Cash Flow | 137.6 M | |
| Total Cashflows From Investing Activities | -293.5 M |
Catalyst Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,202 in Catalyst Pharmaceuticals on April 20, 2025 and sell it today you would lose (99.00) from holding Catalyst Pharmaceuticals or give up 4.5% of portfolio value over 90 days. Catalyst Pharmaceuticals is currently does not generate positive expected returns and assumes 1.9195% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Catalyst, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Catalyst Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalyst Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Catalyst Pharmaceuticals, and traders can use it to determine the average amount a Catalyst Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0291
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CPRX |
Estimated Market Risk
| 1.92 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Catalyst Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Catalyst Pharmaceuticals by adding Catalyst Pharmaceuticals to a well-diversified portfolio.
Catalyst Pharmaceuticals Fundamentals Growth
Catalyst Stock prices reflect investors' perceptions of the future prospects and financial health of Catalyst Pharmaceuticals, and Catalyst Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Catalyst Stock performance.
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.19 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 1.98 B | ||||
| Shares Outstanding | 121.97 M | ||||
| Price To Earning | 23.62 X | ||||
| Price To Book | 3.32 X | ||||
| Price To Sales | 4.89 X | ||||
| Revenue | 491.73 M | ||||
| Gross Profit | 446.46 M | ||||
| EBITDA | 232.9 M | ||||
| Net Income | 163.89 M | ||||
| Cash And Equivalents | 220.79 M | ||||
| Cash Per Share | 2.15 X | ||||
| Total Debt | 3.19 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.79 X | ||||
| Book Value Per Share | 6.51 X | ||||
| Cash Flow From Operations | 239.81 M | ||||
| Earnings Per Share | 1.57 X | ||||
| Market Capitalization | 2.62 B | ||||
| Total Asset | 851.41 M | ||||
| Retained Earnings | 285.16 M | ||||
| Working Capital | 502.93 M | ||||
| Current Asset | 59.9 M | ||||
| Current Liabilities | 3.44 M | ||||
About Catalyst Pharmaceuticals Performance
Evaluating Catalyst Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Catalyst Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Catalyst Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 103.60 | 59.85 | |
| Return On Tangible Assets | 0.24 | 0.25 | |
| Return On Capital Employed | 0.27 | 0.28 | |
| Return On Assets | 0.19 | 0.20 | |
| Return On Equity | 0.23 | 0.24 |
Things to note about Catalyst Pharmaceuticals performance evaluation
Checking the ongoing alerts about Catalyst Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Catalyst Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Catalyst Pharmaceuticals generated a negative expected return over the last 90 days | |
| Over 83.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: What drives Catalyst Pharmaceuticals Inc. stock price - Rapid capital growth - Jammu Links News |
- Analyzing Catalyst Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Catalyst Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Catalyst Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Catalyst Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Catalyst Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Catalyst Pharmaceuticals' stock. These opinions can provide insight into Catalyst Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.